AMSTERDAM (Reuters) – The European medicines watchdog on Tuesday said it was aware of a decision by its U.S. counterpart to pause the administration of Johnson & Johnson’s COVID-19 vaccine due to rare instances of blood clots.
In a statement the European Medicines Agency (EMA) said it is not clear there is a link between the vaccine and the incidents and its safety committee is continuing a review announced last week.
(Reporting by Toby Sterling, Editing by Franklin Paul)
